QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=9341C6F297CEAA1C86450970316EC4A8;jsessionid=22AA568FEAB70D6701FD141CC6DC2279;jsessionid=75E2D23F14E6F19CE6947C486A2B7A74;jsessionid=405F77E00CC6BA3A09347ED0539EBF6F;jsessionid=D2D6F8BA0B81023BC50C015947B74E75;jsessionid=E5577CDBB8F7DED467DCFC930EF8536A (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
3. ATXN2 is a target of N-terminal proteolysis.
4. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
5. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=939235184CEB0A4FED235F93FAB59041;jsessionid=9341C6F297CEAA1C86450970316EC4A8;jsessionid=22AA568FEAB70D6701FD141CC6DC2279;jsessionid=75E2D23F14E6F19CE6947C486A2B7A74;jsessionid=405F77E00CC6BA3A09347ED0539EBF6F;jsessionid=D2D6F8BA0B81023BC50C015947B74E75;jsessionid=E5577CDBB8F7DED467DCFC930EF8536A